Neurological Outcome After 24 Months of Age Following Treatment With Xenon Combined With Moderate Hypothermia After Perinatal Asphyxia
Overview
- Phase
- N/A
- Intervention
- Xenon
- Conditions
- Perinatal Asphyxia
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
- Enrollment
- 69
- Locations
- 3
- Primary Endpoint
- Scores on Bayley scales of infant and toddler development
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
The objective of this study is to document the outcome at 2-3 years of age of participants of the TOBY Xe trial, to provide preliminary information about the later clinical effects of treatment with Xenon gas combined with moderate hypothermia following perinatal asphyxia. The TOBY Xe trial was a randomised controlled trial of inhaled xenon gas combined with hypothermia for the treatment of perinatal asphyxia. The trial primary outcome was changes on magnetic resonance parameters examined prior to discharge from hospital.
Continuing clinical follow-up of trial participants is important following any therapeutic trial and is essential in early phase trials where information on the clinical effects of the intervention are lacking. Therefore, we have set up this study to determine the major clinical and neurological outcomes of participants of the TOBY Xe trial and to determine whether the magnetic resonance parameters in that trial are qualified to predict outcome following neural rescue therapy. This information is necessary for planning further studies of this intervention.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Surviving participants in the TOBY Xenon study
Exclusion Criteria
- •Lack of consent to participate
Arms & Interventions
30% Xenon for 24 hours combined with moderate hypothermia
Surviving children allocated to inhaled xenon combined with moderate hypothermia in the TOBY-Xe trial
Intervention: Xenon
Outcomes
Primary Outcomes
Scores on Bayley scales of infant and toddler development
Time Frame: at 2-3 years of age
Composite scores of the Cognitive, Language and Motor scales scaled to a metric, with a mean of 100, standard deviation of 15, and range of 40 to 160
Relation between magnetic resonance markers and neurodevelopmental outcome
Time Frame: at 2-3 years of age
Peak area Lactate/N Acetyl Aspartate ratio on magnetic resonance spectroscopy and fractional anisotropy on diffusion tensor magnetic resonance imaging
Secondary Outcomes
- Grade of disability(At 2-3 years of age)